Members of the ELASTISLET consortium and Asphalion attended an Innovation Task Force (ITF) meeting in June to obtain feedback on the overall direction of the ELASTISLET project, particularly issues related to the regulatory classification, the overall manufacturing and characterisation of the product as well as the ongoing and future nonclinical testing.
The ITF meeting represented a critical milestone at the midway of the Horizon 2020 project and accordingly the discussion with the EMA was long, intense and extremely fruitful. Conclusions and opinions of the meeting served to highlight both the complications of the field and legislation in general and the ambition and healthy state of the project as it enters a critical phase.
ELASTISLET is now heading into the final half of the project and the lead up to future clinical testing. The outcome of the meeting now paves the way for a final, defined approach to developing a clinic-ready product.
Since June 2015, Asphalion is cooperating with the other members of the consortium on a cross-disciplinary strategy and a unique objective: to develop a smarter strategy to cope with diabetes.
Get to know more about the this European project by visiting http://www.elastislet.eu/en/ or contact us at H2020@asphalion.com
Elastislet: This research project has received funding from the EU’s H2020 framework programme for research and innovation under grant aggreement n. 646075